Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

An early formulation strategy for tablets that is simple and scalable is recommended to ensure fewer downstream problems.

Formulating the Best Approach for Tablets

Pramote Cholayudth previously was the managing director of the Professional Conference Center, Ltd. He currently is a validation consultant to Biolab Co., Ltd., in Thailand. He is the founder and manager of PM consult, cpramote2000@yahoo.com.

The author introduces a practical approach to determining the best estimate of probability for passing multiple stage dissolution tests.

Determining the Best Estimate of Probability of Passing Multiple Stage Tests: Part 2—Dissolution

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Although not easy to do, it is essential because excipients can affect drug-product safety and efficacy.

Bringing Excipients into the Quality-by-Design Paradigm

Meg Rivers is the former senior editor for 

Experts discuss what data to consider when selecting a high-potential drug candidate and how AI can be harnessed in medicinal chemistry drug discovery. 

Early Development Medicinal Chemistry: Utilizing Data and Artificial Intelligence

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

3D cell cultures could provide key avenues to unlocking critical information.

Next Level Interrogation

Mike Hennessy Jr. is the Chairman and CEO of 

Advances in pharmaceutical neuroscience present an opportunity for pharmaceutical companies to stay ahead of the curve.

Major League Moves

Under the two-year task order, ATCC will continue to support the DCEG MEAS program in receiving, processing, storing, analyzing, and distributing clinical specimens from different cancer types.

NCI Awards ATCC Task Order to Provide Cancer Epidemiology Services to Research Community

Sanofi and IGM Biosciences have announced a collaboration agreement for oncology, immunology, and inflammation targets.

Sanofi and IGM Biosciences Announce Collaboration Agreement

Orion is planning to refocus its R&D efforts on the development of new proprietary products focused on cancer and pain.

Orion to Refocus R&D to Cancer and Pain

Huma has acquired AstraZeneca’s digital health platform, and AstraZeneca has become a shareholder of Huma in a partnership to accelerate digital-first patient care.

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development